[Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis].
BACKGROUND
The efficacy of Cyclosporin A 2%eyedrops (CsA2%) as an additive treatment of atopic (AKC) and vernal keratoconjunctivitis (VKC) was evaluated.


METHODS
The symptoms and findings of 26 patients with AKC and 12 patients with VKC with no improvement under conventional therapy, were additionally treated with CsA2% eyedrops and compared over a minimum follow-up period of 3 months to more than 24 months.


RESULTS
The therapy with CsA2% eyedrops was well tolerated and evaluated as effective by the patients. Subtarsal papillae were reduced in 69.2% of the AKC group and in 66.6% of the VKC patients. Trantas dots were reduced or disappeared in about 50% of the AKC group and in the VKC group they had disappeared in more than 50%. Subjective symptoms (e.g. itching) had also been reduced or eliminated.


CONCLUSIONS
CsA2% eyedrops are effective in the treatment of AKC and VKC, reducing objective and subjective signs as well as the need of adding topical steroids in affected patients.
Tomida
I
I
Universitäts-Augenklinik, Abteilung I, Universität Tübingen, Germany.
Schlote
T
T
Bräuning
J
J
Heide
P E
PE
Zierhut
M
M
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009883:Ophthalmic Solutions; D012189:Retrospective Studies; D016896:Treatment Outcome
D009883:Ophthalmic Solutions; D016572:Cyclosporine